Mapping Tau PET Tracers to Correlate with Cognitive Decline in Different Patient Cohorts for a More Biologically Driven Staging of Alzheimer’s Disease & Other Neurological Diseases
Time: 10:00 am
day: Conference Day Two
Details:
- Exploring plasma p217+tau to show promise for separating either intermediate/advanced stage AD from lower stage AD to provide prognostic information and inform better selection for trials and disease modifying therapies
- Employing biological PET stages recommended by NIA-AA revised criteria to show disease progression with plasma p217+tau as an incremental stepwise trend capable of determining population-specific patient improvement on drug
- Navigating utility and reproducibility challenges in implementing plasma p217+tau for group level discrimination between disease stages across the globe
- Looking ahead to developing risk prediction models to combine several factors to accurately predict individual-level disease stages
